Largest biotechnology: biological products (no diagnostic substances) companies
Every US-listed biotechnology: biological products (no diagnostic substances) company we cover, 160 of them, ranked by market capitalisation, with revenue and earnings taken from their SEC filings.
Combined market cap
$866.523 B
0.9% of all US-listed value
Companies
160
Ranked #23 of 152 industries
Average
$5.416 B
Mean market cap per company
| # | Name | Market cap | Close | Session | Country |
|---|---|---|---|---|---|
| 1 | AmgenAMGN | $223.3B | $413.08 | +2.60% | United States |
| 2 | Gilead SciencesGILD | $182.1B | $146.85 | +1.82% | United States |
| 3 | ModernaMRNA | $78.4B | $196.48 | +4.81% | United States |
| 4 | Argenx SeARGX | $57.6B | $928.44 | -0.22% | Netherlands |
| 5 | Revolution MedicinesRVMD | $43.1B | $200.87 | +0.50% | United States |
| 6 | BiogenBIIB | $32.8B | $222.15 | -0.33% | United States |
| 7 | BioNTech SEBNTX | $23.9B | $95.25 | -0.50% | Germany |
| 8 | Neurocrine BiosciencesNBIX | $14.6B | $143.47 | -1.40% | United States |
| 9 | ExelixisEXEL | $14.5B | $58.44 | +0.19% | United States |
| 10 | Halozyme TherapeuticsHALO | $12.6B | $110.79 | +0.97% | United States |
| 11 | Bio-TechneTECH | $11.4B | $72.53 | +0.14% | United States |
| 12 | ImmunityBioIBRX | $10.3B | $9.75 | +0.62% | United States |
| 13 | Twist BioscienceTWST | $10.3B | $155.65 | -6.78% | United States |
| 14 | VaxcytePCVX | $9.96B | $66.96 | +0.39% | United States |
| 15 | Krystal BiotechKRYS | $9.61B | $324.57 | -0.69% | United States |
| 16 | QiagenQGEN | $9.23B | $44.79 | -1.88% | Netherlands |
| 17 | Kymera TherapeuticsKYMR | $9.01B | $108.35 | +2.24% | United States |
| 18 | RepligenRGEN | $8.18B | $167.22 | -4.37% | United States |
| 19 | ImmunovantIMVT | $6.62B | $32.04 | -0.22% | United States |
| 20 | Iovance BiotherapeuticsIOVA | $5.85B | $12.92 | -0.35% | United States |
| 21 | Kodiak SciencesKOD | $5.72B | $91.08 | -1.36% | United States |
| 22 | CG OncologyCGON | $5.53B | $62.38 | -1.98% | United States |
| 23 | Scholar RockSRRK | $5.14B | $42.20 | -0.59% | United States |
| 24 | CRISPR TherapeuticsCRSP | $5.06B | $52.35 | -3.06% | Switzerland |
| 25 | Adaptive BiotechnologiesADPT | $4.19B | $26.28 | -2.31% | United States |
| 26 | Relay TherapeuticsRLAY | $3.93B | $17.95 | -4.22% | United States |
| 27 | Tarsus PharmaceuticalsTARS | $3.44B | $73.61 | -0.68% | United States |
| 28 | Denali TherapeuticsDNLI | $3.06B | $19.16 | -0.62% | United States |
| 29 | Beam TherapeuticsBEAM | $2.56B | $24.77 | -1.82% | United States |
| 30 | Recursion PharmaceuticalsRXRX | $2.29B | $4.27 | -7.78% | United States |
| 31 | AlvotechALVO | $2.28B | $5.85 | -4.72% | Luxembourg |
| 32 | Adma BiologicsADMA | $2.27B | $10.14 | -0.39% | United States |
| 33 | Biocryst PharmaceuticalsBCRX | $2.15B | $8.40 | +5.66% | United States |
| 34 | VericelVCEL | $2.09B | $40.74 | +1.72% | United States |
| 35 | Vir BiotechnologyVIR | $1.95B | $11.52 | -0.69% | United States |
| 36 | NovavaxNVAX | $1.85B | $11.22 | -0.88% | United States |
| 37 | MesoblastMESO | $1.81B | $13.94 | +2.42% | Australia |
| 38 | ImmunocoreIMCR | $1.51B | $29.41 | -0.47% | United Kingdom |
| 39 | Maze TherapeuticsMAZE | $1.46B | $26.25 | -0.68% | United States |
| 40 | Taysha Gene TherapiesTSHA | $1.44B | $4.43 | +0.91% | United States |
| 41 | Inhibrx BiosciencesINBX | $1.37B | $93.36 | -0.05% | United States |
| 42 | Hemab TherapeuticsCOAG | $1.34B | $28.70 | +1.16% | United States |
| 43 | Replimune GroupREPL | $1.24B | $13.20 | -0.38% | United States |
| 44 | ImmaticsIMTX | $1.11B | $7.45 | -0.67% | Germany |
| 45 | Vor BiopharmaVOR | $1.11B | $18.78 | +2.57% | United States |
| 46 | MeiraGTxMGTX | $1.04B | $10.82 | +2.08% | United States |
| 47 | Cullinan TherapeuticsCGEM | $1.01B | $15.63 | -3.81% | United States |
| 48 | Odyssey TherapeuticsODTX | $868.9M | $18.08 | -0.28% | United States |
| 49 | Monte Rosa TherapeuticsGLUE | $867.6M | $10.17 | +3.04% | United States |
| 50 | SL ScienceSLBT | $846.7M | $1.51 | -0.66% | Taiwan |
| 51 | Sana BiotechnologySANA | $814.3M | $2.72 | -1.09% | United States |
| 52 | Candel TherapeuticsCADL | $751.4M | $9.82 | -0.51% | United States |
| 53 | Attovia TherapeuticsATTO | $749.6M | $16.42 | -6.17% | United States |
| 54 | Ginkgo BioworksDNA | $738.0M | $11.47 | -7.58% | United States |
| 55 | Solid BiosciencesSLDB | $734.5M | $6.85 | -1.01% | United States |
| 56 | Prime MedicinePRME | $707.4M | $3.90 | +11.43% | United States |
| 57 | 4D Molecular TherapeuticsFDMT | $695.5M | $12.59 | +0.24% | United States |
| 58 | Aura BiosciencesAURA | $669.9M | $6.46 | +4.70% | United States |
| 59 | DBV TechnologiesDBVT | $578.2M | $9.77 | -2.10% | France |
| 60 | Electra TherapeuticsETRA | $574.9M | $9.16 | -6.72% | United States |
| 61 | Valneva SEVALN | $557.0M | $5.87 | +0.17% | France |
| 62 | RegenxbioRGNX | $501.4M | $7.60 | +1.95% | United States |
| 63 | Allogene TherapeuticsALLO | $494.1M | $1.43 | -2.06% | United States |
| 64 | Autolus TherapeuticsAUTL | $481.8M | $1.81 | +1.12% | United Kingdom |
| 65 | ProkidneyPROK | $474.6M | $1.57 | -1.88% | United States |
| 66 | Tectonic TherapeuticTECX | $444.0M | $22.71 | +1.34% | United States |
| 67 | Entera BioENTX | $436.5M | $2.51 | -0.79% | Israel |
| 68 | AgomAb TherapeuticsAGMB | $433.4M | $8.80 | -0.45% | Belgium |
| 69 | Editas MedicineEDIT | $422.3M | $2.75 | +0.73% | United States |
| 70 | Eikon TherapeuticsEIKN | $408.4M | $7.54 | +0.40% | United States |
| 71 | Zura BioZURA | $399.6M | $4.17 | +5.30% | Cayman Islands |
| 72 | Kyverna TherapeuticsKYTX | $381.6M | $6.17 | +0.16% | United States |
| 73 | Fennec PharmaceuticalsFENC | $363.0M | $10.36 | +0.10% | United States |
| 74 | C4 TherapeuticsCCCC | $346.9M | $2.82 | -2.08% | United States |
| 75 | Artiva BiotherapeuticsARTV | $342.2M | $7.00 | -3.71% | United States |
| 76 | AgenusAGEN | $341.9M | $7.57 | +1.07% | United States |
| 77 | OcugenOCGN | $339.1M | $1.00 | -3.85% | United States |
| 78 | Cabaletta BioCABA | $334.0M | $1.97 | -2.48% | United States |
| 79 | Scribe TherapeuticsSCTX | $332.6M | $17.57 | +7.59% | United States |
| 80 | SurrozenSRZN | $295.5M | $25.15 | -4.64% | United States |
| 81 | X4 PharmaceuticalsXFOR | $278.6M | $2.81 | +1.44% | United States |
| 82 | Lexeo TherapeuticsLXEO | $271.6M | $3.31 | +0.30% | United States |
| 83 | Inhibikase TherapeuticsIKT | $270.7M | $1.94 | -2.02% | United States |
| 84 | SAB BiotherapeuticsSABS | $262.0M | $2.88 | -1.71% | United States |
| 85 | Palisade BioPALI | $257.9M | $1.48 | -0.67% | United States |
| 86 | Fate TherapeuticsFATE | $257.6M | $2.15 | -6.11% | United States |
| 87 | Sutro BiopharmaSTRO | $243.1M | $14.66 | +1.45% | United States |
| 88 | Lineage Cell TherapeuticsLCTX | $239.7M | $0.95 | +1.03% | United States |
| 89 | Century TherapeuticsIPSC | $231.8M | $1.28 | -3.03% | United States |
| 90 | Protalix BioTherapeuticsPLX | $218.3M | $2.71 | -0.73% | Israel |
| 91 | InvivydIVVD | $214.8M | $0.73 | -9.65% | United States |
| 92 | AlectorALEC | $214.4M | $1.92 | +6.08% | United States |
| 93 | CompugenCGEN | $203.4M | $2.15 | -3.15% | Israel |
| 94 | Compass TherapeuticsCMPX | $183.7M | $1.02 | +2.19% | United States |
| 95 | Precision BiosciencesDTIL | $172.5M | $6.25 | +0.81% | United States |
| 96 | Innate PharmaIPHA | $169.8M | $1.52 | -4.40% | France |
| 97 | Cardiol TherapeuticsCRDL | $159.3M | $1.32 | +0.76% | Canada |
| 98 | Coherus OncologyCHRS | $156.0M | $1.01 | -1.94% | United States |
| 99 | Protara TherapeuticsTARA | $153.1M | $2.59 | +1.37% | United States |
| 100 | Voyager TherapeuticsVYGR | $152.2M | $2.47 | +0.41% | United States |
Showing 1โ100 of 160 companies. One row per company, with secondary share classes folded into their primary listing. Updated 9 Oct 2026.
Sectors biotechnology: biological products (no diagnostic substances) companies sit in
Other industries
Semiconductors 100Computer Software: Programming Data Processing 77Computer Software: Prepackaged Software 234Computer Manufacturing 10Biotechnology: Pharmaceutical Preparations 500Major Banks 245Industrial Machinery/Components 212Catalog/Specialty Distribution 30Business Services 92Commercial Banks 35Auto Manufacturing 29Integrated oil Companies 16Oil & Gas Production 116Investment Bankers/Brokers/Service 68Real Estate Investment Trusts 175Department/Specialty Retail Stores 13Telecommunications Equipment 84Electronic Components 21Beverages (Production/Distribution) 36Electric Utilities: Central 61Finance: Consumer Services 165Consumer Electronics/Appliances 23Medical Specialities 44Property-Casualty Insurers 68All industries โ
Figures come from SEC filings and daily market prices. Companies listed only outside the US are not covered: see methodology.